CANCER CALCULUS
Big fines and settlements barely dent cancer drugmakers’ revenues, fail to deter wrongdoing
An ICIJ review found nearly $1.7 billion in settlements and fines over a 15 year period. But experts said many companies see the payouts as the cost of doing business.



